antiplatelets drug

Browse trials
V2  
List  

treatment    comparator  All cause death Coronary death Coronary event Adverse events Bleeding Bleeding Cardiovascular death MACE Fatal MI Amputation Revascularization Major bleeding Major bleeding Haemmorhagic stroke Vascular death Fatal stroke Non fatal stroke Non fatal MI Vascular events Fatal bleeding Fatal bleeding Non cerebral major bleeding ischemic stroke  intracranial hemorrhage Non vascular death stroke (fatal and non fatal)  stroke (fatal and non fatal)  myocardial infarction (fatal and non fatal)  Deep vein thrombosis  cardiac death cardiovascular events Stent thrombosis (any, end of follow up) Stent thrombosis (any, end of follow up) target lesion revascularisation  angiographic restenosis  4 yr mortality from all causes  4 yr TLR  4 yr MI 4 yr death or MI  4 yr stent thrombosis 4y stent thrombosis (ARC) CABG non cardiovascular death  proximal DVT  non-fatal pulmonary embolism  wound haematoma / infection  fatal pulmonary embolism  Peripheral vascular events  Gastrointestinal Bleeding Peptic ulcer  Hematuria  Major gastrointestinal bleeding death, MI, unplanned revascularization  ischemic events + bleeding  major bleeding TIMI  TIMI minor bleeding cardiovascular death, MI, stroke late stent thrombosis (31days - 1year) target-vessel revascularization 2 yr TLR  2 yr MACE  in-lesion binary restenosis  2 yr Death (all cause)  Acute stent thrombosis (<=24h) sub acute stent thrombosis (1-30 days) refractory ischemia fatal bleeding  stable angina  unstable angina  Major or minor TIMI bleeding Urgent target-vessel revascularization  all cause death, MI, stroke fatal hemorrhagic stroke  non fatal hemorrhagic stroke  net benefit non pulmonary embolism death any bleedings GUSTO severe/moderate bleeding  Cardiovascular death/MI/stent thrombosis stent thrombosis      
Cilostazolpercutaneous coronary intervention, in all type of patients vs aspirin-------NS------------------------------------------------------------------------
Cilostazolpercutaneous coronary intervention, in all type of patients vs ticlopidine + aspirin-------NS------------------------------------------------------------------------
Elinogrelacute coronary syndrome, in STEMI patients vs placebo-----------NSNS---NSNS--------------------------------------------------------------
Elinogrelacute myocardial infarction, in all type of patients vs placebo-----------NSNS---NSNS--------------------------------------------------------------
Ticagreloracute coronary syndrome, in ACS (excluding AMI) vs clopidogrel by 21% ---NSNS-----NSNS- by 20% -------NS-NSNSNS by 16% -- by 15% -----------------------------------NS---- by 16% --------
Ticagreloracute coronary syndrome, in all type of patients vs clopidogrel by 21% ---NSNS-----NSNS- by 20% -------NS-NSNSNS by 16% -- by 15% -----------------------------------NS---- by 16% --------
Ticagrelorcardiovascular prevention, in all type of patients vs placebo (on top aspirin)NS by 23% ---- by 15% ---- by 126% by 126% ------NSNS--NS- by 21% by 21% by 17% -- by 15% ------------------------- by 15% -----------------------
Ticagrelorcardiovascular prevention, in secondary prevention in patients with CAD vs placebo (on top aspirin)NS by 23% ---- by 15% ---- by 126% by 126% ------NSNS--NS- by 21% by 21% by 17% -- by 15% ------------------------- by 15% -----------------------
Ticagrelorcardiovascular prevention, in secondary prevention vs placebo (on top aspirin)NS by 23% ---- by 15% ---- by 126% by 126% ------NSNS--NS- by 21% by 21% by 17% -- by 15% ------------------------- by 15% -----------------------
Ticagrelorcardiovascular prevention, in secondary prevention in patients with intermittent claudication vs clopidogrel--------------------------------------------------------------------------------
Ticagrelorperipheral vascular diseases, in all type of patient vs clopidogrel--------------------------------------------------------------------------------
Ticagrelorpost myocardial infarction, in all type of patient vs placebo (on top aspirin)NS by 23% ---- by 15% ---- by 126% by 126% ------NSNS--NS- by 21% by 21% by 17% -- by 15% ------------------------- by 15% -----------------------
Atopaxaracute coronary syndrome, in all type of patients vs placebo--------------------------------------------------------------------------------
Atopaxaracute coronary syndrome, in ACS (excluding AMI) vs placebo--------------------------------------------------------------------------------
Aspirinacute coronary syndrome, in STEMI patients vs control------NS---------NSNS------------NS-----------NS-------------------------------------
Aspirinacute coronary syndrome, in STEMI patients vs placebo------ by 21% ----NSNS--- by 42% by 54% ------------ by 26% -----------NS-------------------------------------
Aspirinacute coronary syndrome, in ACS (excluding AMI) vs control-----------NSNS-NS--NS------NS-----NS-------------------------------------------------
Aspirinacute coronary syndrome, in ACS (excluding AMI) vs placebo-----------NSNS- by 37% -NS by 43% ------NS-- by 72% -- by 37% ----------------------------------NS--------------
Aspirinacute coronary syndrome, in all type of patients vs control-----------NSNS-NS--NS------NS-----NS-------------------------------------------------
Aspirinacute coronary syndrome, in all type of patients vs placebo-----------NSNS- by 37% -NS by 43% ------NS-- by 72% -- by 37% ----------------------------------NS--------------
Aspirinacute myocardial infarction, in all type of patients vs control------NS---------NSNS------------NS-----------NS-------------------------------------
Aspirinacute myocardial infarction, in all type of patients vs placebo------ by 21% ----NSNS--- by 42% by 54% ------------ by 26% -----------NS-------------------------------------
AspirinCABG surgery, in all type of patients vs placebo------NS---------NSNS------NS-----NS-------------------------------------------------
Aspirincardiovascular prevention, in patients without established disease vs no treatmentNSNSNS---NS-NS----NS-NSNSNS----NS--NSNSNS--NS----------------NS by 247% --NS---------------NSNS-----------
Aspirincardiovascular prevention, in patients without established disease vs placeboNSNS by 21% ---NS-NS-- by 32% by 32% NS-NSNS by 24% -NSNS- by 16% --NSNSNS-- by 11% ----------------NS by 26% by 32% NS by 58% ---------------NS----NSNS------
Aspirincardiovascular prevention, in diabetic patients vs no treatmentNSNSNS---NS-NS-NS----NS-NS-------NSNSNS--NS----------------NS-------------------NSNS-----------
Aspirincardiovascular prevention, in diabetic patients vs placeboNSNSNS---NS-NS------NS-NS-------NSNSNS--NS----------------NS-------------------NS------------
Aspirincardiovascular prevention, in all type of patients vs no treatmentNSNSNS---NS------NS--NSNS----NS--NSNSNS--NS----------------- by 247% --NS----------------------------
Aspirincardiovascular prevention, in all type of patients vs placeboNSNS by 24% ---NS---- by 32% by 32% NS--NS by 26% -NSNS- by 16% --NSNSNS-- by 11% ----------------- by 26% by 32% NS by 58% --------------------NSNS------
Aspirincardiovascular prevention, in secondary prevention in patients with intermittent claudication vs placeboNS-------NS-----NSNSNSNSNSNSNSNS-----NS----------------------------------------------------
Aspirincardiovascular prevention, in secondary prevention in patients with CAD vs placeboNS----- by 27% - by 58% -------NS by 30% ------NS----- by 29% -------------------------------------------------
Aspirincardiovascular prevention, in primary prevention vs no treatmentNSNSNS---NS------NS--NSNS----NS--NSNSNS--NS----------------- by 247% --NS----------------------------
Aspirincardiovascular prevention, in primary prevention vs placeboNSNS by 24% ---NS---- by 32% by 32% NS--NS by 26% -NSNS- by 16% --NSNSNS-- by 11% ----------------- by 26% by 32% NS by 58% --------------------NSNS------
Aspirindiabetes type 2, in patients without cardiovascular disease vs no treatmentNSNSNS---NS-NS-NS----NS-NS-------NSNSNS--NS----------------NS-------------------NSNS-----------
Aspirindiabetes type 2, in patients without cardiovascular disease vs placeboNSNSNS---NS-NS------NS-NS-------NSNSNS--NS----------------NS-------------------NS------------
Aspirindiabetes type 2, in all type of patients vs no treatmentNSNSNS---NS-NS-NS----NS-NS-------NSNSNS--NS----------------NS-------------------NS